niacin has been researched along with Chemical and Drug Induced Liver Injury in 57 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatotoxicity is a potential side effect of niacin therapy for hypercholesterolemia, ranging from mild aminotransferase elevation to fulminant hepatic failure." | 3.68 | Transient focal hepatic defects related to sustained-release niacin. ( Lawrence, SP, 1993) |
| "Niacin (nicotinic acid) is a widely used agent in the treatment of hyperlipidemias characterized by elevated low-density lipoprotein and very-low-density lipoprotein." | 3.68 | Hepatotoxicity associated with sustained-release niacin. ( Berry, RS; Dalton, TA, 1992) |
| "Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain." | 2.78 | HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. ( , 2013) |
| "Niacin has beneficial effects on plasma lipoproteins and has demonstrated clinical benefits in reducing cardiovascular events and atherosclerosis progression." | 2.44 | Safety considerations with niacin therapy. ( Bays, HE; Guyton, JR, 2007) |
| " Many clinical trials have been designed to evaluate pharmacologic compounds in the treatment of the dyslipidemias and they seem to have shown a safe profile, both in the experiment phases and in post-marketing observation studies." | 2.42 | Hepatotoxicity of hypolipidemic drugs. ( Parra, JL; Reddy, KR, 2003) |
| " Adverse effects on the liver from both unmodified and time-release preparations have been recognized for many years." | 2.38 | Hepatic toxicity of unmodified and time-release preparations of niacin. ( Calvert, RJ; Hathcock, JN; Rader, JI, 1992) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| "Pretreatment with caffeine, nicotinic acid or non-substituted pyrazinoic acid activated the LPS/D-GalN induced elevation of plasma IL-10 levels at 1 and 2 h, although there were no statistically significant differences in IL-10 levels between control and nicotinic acid or non-substituted pyrazinoic acid treated rats." | 1.35 | Protective effects of coffee-derived compounds on lipopolysaccharide/D-galactosamine induced acute liver injury in rats. ( Akashi, I; Hirano, T; Kagami, K; Oka, K, 2009) |
| " Current drug labeling warns of an increased risk of adverse events with statin and niacin combinations." | 1.34 | Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). ( Alsheikh-Ali, AA; Karas, RH, 2007) |
| " Successful and safe therapy requires ongoing supervision and instruction by qualified health care providers to monitor the efficacy of therapy and minimize niacin's potential for adverse effects." | 1.30 | ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists. ( , 1997) |
| " While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD." | 1.29 | Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice. ( Altrichter, S; Dietrich, A; Ehrlich, W; Grätz, R; Klewer, M; Kröger, H; Kurpisz, M; Miesel, R, 1996) |
| "Niacin was well tolerated in 83% of the nontransplant group (n = 65) at an average dose of 2." | 1.28 | Niacin revisited: clinical observations on an important but underutilized drug. ( Henkin, Y; Hurst, DC; Oberman, A; Segrest, JP, 1991) |
| " This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication." | 1.28 | Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. ( Allison, TG; Etchason, JA; Gau, GT; Kottke, BA; Marttila, JK; Miller, TD; Squires, RW, 1991) |
| " Evidence exists that sustained-release niacin, with respect to both dosage and severity, is more hepatotoxic than crystalline niacin." | 1.28 | Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. ( Henkin, Y; Johnson, KC; Segrest, JP, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (24.56) | 18.7374 |
| 1990's | 19 (33.33) | 18.2507 |
| 2000's | 10 (17.54) | 29.6817 |
| 2010's | 13 (22.81) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Hu, D | 1 |
| Zhang, L | 1 |
| Jiang, R | 1 |
| Liao, C | 1 |
| Xu, J | 1 |
| Jiang, S | 1 |
| Yang, Y | 1 |
| Lin, L | 1 |
| Huang, J | 1 |
| Shen, Y | 1 |
| Tang, L | 1 |
| Li, L | 1 |
| Schaffellner, S | 1 |
| Stadlbauer, V | 1 |
| Sereinigg, M | 1 |
| Mìller, H | 1 |
| Högenauer, C | 1 |
| Fickert, P | 1 |
| Krumnikl, J | 1 |
| Lackner, C | 1 |
| Kniepeiss, D | 1 |
| Stauber, RE | 1 |
| Landmesser, U | 1 |
| Noff, T | 1 |
| Insel, J | 1 |
| Rosenson, RS | 1 |
| Gotto, AM | 1 |
| Nicholls, SJ | 1 |
| Akashi, I | 1 |
| Kagami, K | 1 |
| Hirano, T | 1 |
| Oka, K | 1 |
| Parra, JL | 1 |
| Reddy, KR | 1 |
| Xydakis, AM | 1 |
| Jones, PH | 1 |
| RANDOLPH, H | 1 |
| JOSEPH, S | 1 |
| BERNSTEIN, A | 1 |
| SIMON, F | 1 |
| OJI, N | 1 |
| SPATZ, M | 1 |
| FRANK, O | 1 |
| BAKER, H | 1 |
| LEEVY, CM | 1 |
| SCHREIBER, FK | 1 |
| Rizakallah, GS | 1 |
| Mertens, MK | 1 |
| Brown, ML | 1 |
| Sanner, L | 1 |
| Bertolami, MC | 1 |
| Madariaga, MG | 1 |
| Alsheikh-Ali, AA | 1 |
| Karas, RH | 1 |
| Guyton, JR | 1 |
| Bays, HE | 1 |
| Bhardwaj, SS | 1 |
| Chalasani, N | 1 |
| Tishler, M | 1 |
| Abramov, AL | 1 |
| Patterson, DJ | 1 |
| Dew, EW | 1 |
| Gyorkey, F | 1 |
| Graham, DY | 1 |
| Jungnickel, PW | 2 |
| Maloley, PA | 2 |
| Reimund, E | 1 |
| Ramos, A | 1 |
| Lavie, CJ | 1 |
| Milani, RV | 1 |
| Coppola, A | 1 |
| Brady, PG | 1 |
| Nord, HJ | 1 |
| Lawrence, SP | 1 |
| Kröger, H | 1 |
| Klewer, M | 1 |
| Grätz, R | 1 |
| Dietrich, A | 1 |
| Ehrlich, W | 1 |
| Altrichter, S | 1 |
| Kurpisz, M | 1 |
| Miesel, R | 1 |
| Tatò, F | 1 |
| Vega, GL | 1 |
| Grundy, SM | 1 |
| Scheer, MS | 1 |
| Perlmutter, S | 1 |
| Ross, W | 1 |
| Katz, DS | 1 |
| Gavilán, JC | 1 |
| Bermúdez, FJ | 1 |
| Belmonte, A | 1 |
| González-Santos, P | 1 |
| Dalton, TA | 1 |
| Berry, RS | 1 |
| Rader, JI | 1 |
| Calvert, RJ | 1 |
| Hathcock, JN | 1 |
| Malloy, MJ | 1 |
| Frost, PH | 2 |
| Kane, JP | 1 |
| Henkin, Y | 2 |
| Oberman, A | 1 |
| Hurst, DC | 1 |
| Segrest, JP | 2 |
| Palumbo, PJ | 1 |
| Etchason, JA | 1 |
| Miller, TD | 1 |
| Squires, RW | 1 |
| Allison, TG | 1 |
| Gau, GT | 1 |
| Marttila, JK | 1 |
| Kottke, BA | 1 |
| Hodis, HN | 1 |
| Johnson, KC | 1 |
| Mullin, GE | 1 |
| Greenson, JK | 1 |
| Mitchell, MC | 1 |
| Ferenchick, G | 1 |
| Rovner, D | 1 |
| Knopp, RH | 1 |
| Clementz, GL | 1 |
| Holmes, AW | 1 |
| Kingreen, JC | 1 |
| Breger, G | 1 |
| Gopalan, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients[NCT03973203] | 15 participants (Actual) | Interventional | 2014-06-01 | Completed | |||
| NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance[NCT04538521] | 3 participants (Actual) | Interventional | 2019-02-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for niacin and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Hepatotoxicity of hypolipidemic drugs.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Female; F | 2003 |
Toxicity of antilipidemic agents: facts and fictions.
Topics: Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Humans; Hydrox | 2003 |
Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?
Topics: Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Drug Therapy, Combination; Huma | 2005 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Lipid-lowering agents that cause drug-induced hepatotoxicity.
Topics: Azetidines; Chemical and Drug Induced Liver Injury; Cholesterol Ester Transfer Proteins; Ezetimibe; | 2007 |
Niacin-induced hepatitis and thrombocytopenia after 10 years of niacin use.
Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Male; Niacin; Thrombocytopenia; Time Factors | 1994 |
Hepatic toxicity of unmodified and time-release preparations of niacin.
Topics: Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Humans; Niacin | 1992 |
A report on the first fifty years of the Nutrition Research Laboratories, Hyderabad.
Topics: Aflatoxins; Anemia, Hypochromic; Chemical and Drug Induced Liver Injury; Child Nutritional Physiolog | 1970 |
1 trial available for niacin and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Death, Sudden, Cardiac; Delayed | 2013 |
47 other studies available for niacin and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Nicotinic Acid against Acetaminophen-Induced Hepatotoxicity via Sirt1/Nrf2 Antioxidative Pathway in Mice.
Topics: Acetaminophen; Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Kelch-Like ECH-Associa | 2021 |
Niacin-Associated Acute Hepatotoxicity Leading to Emergency Liver Transplantation.
Topics: Athletes; Chemical and Drug Induced Liver Injury; Emergencies; Female; Humans; Liver Transplantation | 2017 |
The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin.
Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Female; Humans; Hypolipidemic A | 2013 |
Energy drinks and the unwanted buzz: a case report.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Chest Pai | 2013 |
When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events.
Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Female; Humans; Hypolipidemic A | 2013 |
Niacin's effect on cardiovascular risk: have we finally learned our lesson?
Topics: Arterial Occlusive Diseases; Atherosclerosis; Chemical and Drug Induced Liver Injury; Cholesterol, H | 2014 |
Protective effects of coffee-derived compounds on lipopolysaccharide/D-galactosamine induced acute liver injury in rats.
Topics: Alanine Transaminase; Alkaloids; Animals; Aspartate Aminotransferases; Caffeine; Chemical and Drug I | 2009 |
Toxic hepatitis with jaundice occuring in a patient treated with isoniazid.
Topics: Chemical and Drug Induced Liver Injury; Hepatitis; Hepatitis A; Isoniazid; Jaundice; Niacin; Nicotin | 1953 |
Chlorpromazine and iproniazid toxic hepatitis in the same patient.
Topics: Chemical and Drug Induced Liver Injury; Chlorpromazine; Hepatitis; Hepatitis A; Iproniazid; Niacin; | 1959 |
The inactivation of cortisol in experimental diabetic animals.
Topics: Anatomy; Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Diabetes M | 1963 |
PATHOGENETIC STUDIES OF EXPERIMENTALLY INDUCED HEART LESIONS AND THEIR RELATION TO THE CARCINOID SYNDROME.
Topics: Chemical and Drug Induced Liver Injury; Deficiency Diseases; Diet; Guinea Pigs; Heart Diseases; Hepa | 1964 |
VITAMIN-BINDING CAPACITY OF EXPERIMENTALLY INJURED LIVER.
Topics: Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Folic Acid; Hepatitis; Leuco | 1964 |
[ON THE PROBLEM OF NICOTINIC ACID SIDE-EFFECTS].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy; Hepatitis; Hepatitis A; Niacin; Nicotinic Acid | 1964 |
[Mechanisms of hepatotoxicity].
Topics: Chemical and Drug Induced Liver Injury; Clofibrate; Drug Interactions; Humans; Hydroxymethylglutaryl | 2005 |
Drug-related hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Dietary Supplements; Humans; Hypolipidemic Agents; Niacin | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug | 2007 |
[Niacin-induced hepatitis].
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Niacin | 1984 |
Niacin hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Cholestasis; Humans; Liver; Liver Function Tests; Mal | 1983 |
Pharmacoepidemiology of niacin.
Topics: Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Humans; Niacin; Research Design | 1995 |
Safety and side effects of sustained-release niacin.
Topics: Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Humans; Niacin | 1994 |
Niacin-induced hepatotoxicity: unusual presentations.
Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Female; Humans; Male; Mi | 1994 |
Transient focal hepatic defects related to sustained-release niacin.
Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Fatty Liver; Female; Hum | 1993 |
Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Animals; Aspartate Aminotransferases; | 1996 |
ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists.
Topics: Chemical and Drug Induced Liver Injury; Drug Monitoring; Gastrointestinal Diseases; Humans; Hyperlip | 1997 |
Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase.
Topics: Acyltransferases; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Humans; Liver; Liver Dis | 1998 |
Ultrasonographic findings in niacin-induced hepatitis.
Topics: Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Humans; Liver; Male; Middle Age | 1999 |
[Niacin-induced hepatitis].
Topics: Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Niacin | 2002 |
Hepatotoxicity associated with sustained-release niacin.
Topics: Aged; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Female; Humans; Hyperlipi | 1992 |
Niacin--the long and the short of it.
Topics: Chemical and Drug Induced Liver Injury; Hepatic Encephalopathy; Humans; Male; Middle Aged; Niacin | 1991 |
Niacin revisited: clinical observations on an important but underutilized drug.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Cholesterol, HDL; Cholesterol, VLDL; Delayed-Ac | 1991 |
Comment: adverse-effect profile of sustained-release niacin.
Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Humans; Male; Middle Age | 1991 |
Rediscovery of crystalline niacin.
Topics: Chemical and Drug Induced Liver Injury; Humans; Hyperlipidemias; Niacin | 1991 |
Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.
Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Female; Humans; Hyperlip | 1991 |
All niacin is not the same.
Topics: Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Niacin; Therapeutic Equivalency | 1991 |
Acute hepatic failure associated with the use of low-dose sustained-release niacin.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Hepatic E | 1990 |
Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin.
Topics: Chemical and Drug Induced Liver Injury; Crystallization; Delayed-Action Preparations; Female; Humans | 1990 |
Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.
Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Hepatic Encephalopathy; | 1989 |
Hepatitis and hematemesis complicating nicotinic acid use.
Topics: Adult; Chemical and Drug Induced Liver Injury; Hematemesis; Humans; Liver; Liver Function Tests; Mal | 1989 |
Niacin and hepatic failure.
Topics: Aged; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Fatigue; Gastrointestinal | 1989 |
Nicotinic acid-induced fulminant hepatic failure.
Topics: Chemical and Drug Induced Liver Injury; Hepatic Encephalopathy; Humans; Hypercholesterolemia; Liver | 1987 |
[Pellagra in morazone abuse].
Topics: Adult; Analgesics, Opioid; Antipyrine; Chemical and Drug Induced Liver Injury; Female; Humans; Male; | 1984 |